MedTrace Logo

Diabetes Treatment With Glucobay in Combination With Sulfonylurea

NCT01613105 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4564

Last updated 2013-06-26

No results posted yet for this study

Summary

In this prospective, non interventional, observational Post Marketing Survelliance study data are obtained on the efficacy, safety and tolerability of Glucobay treatment on top of sulfonylurea under daily life treatment conditions.Specifically investigated is the influence of Glucobay on Post Prandial Blood Glucose and HbA1c as well as on pateint's weight when added to an already existing sulfonylurea therapy.The study is planned to carried out in 25000 - 30000 patients from 200 trial sites in India.The Post Marketing Survelliance study will be performed with commercially available medication prescribed within regular practice of the physician. No other examination will be performed than would be done without Post Marketing Survelliance study.

Conditions

Interventions

DRUG

Acarbose (Precose/Glucobay, BAYG5421)

Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • India

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01613105 on ClinicalTrials.gov